Skip to main content
Top
Published in: Neurological Sciences 12/2013

01-12-2013 | Review Article

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

Authors: Massimo Filippi, Maria A. Rocca, Stefano Bastianello, Giancarlo Comi, Paolo Gallo, Massimo Gallucci, Angelo Ghezzi, Maria Giovanna Marrosu, Giorgio Minonzio, Patrizia Pantano, Carlo Pozzilli, Gioacchino Tedeschi, Maria Trojano, Andrea Falini, Nicola De Stefano

Published in: Neurological Sciences | Issue 12/2013

Login to get access

Abstract

MRI is highly sensitive in detecting focal white matter lesions in multiple sclerosis (MS). For this reason, it has been formally included in the diagnostic workup of patients with clinically isolated syndromes suggestive of MS, through the definition of ad hoc sets of criteria to show disease dissemination in space and time. MRI is used in virtually all clinical trials of the disease as a surrogate measure of treatment response. Several guidelines have been published to help characterizing the imaging features on conventional MR sequences of “typical” MS lesions and work has also been performed to identify “red flags” which should alert the clinicians to exclude possible alternative conditions. Despite this, the application of the available guidelines and criteria in daily life clinical practice is still limited and varies among and within countries (including Italy) due to regulatory issues and heterogeneity of MRI facilities. It is crucial for neurologists and neuroradiologists to become familiar with these criteria to improve the quality of their diagnostic assessment. In patients with established MS, the main problem is to define standard procedures for monitoring the course of the disease and treatment response. This review aims at providing daily life guidelines to clinicians for a correct application of MRI in the workup of patients suspected of having MS as well as in the monitoring of disease evolution in those with established MS. It also offers clues for the standardization of MRI studies and relative reporting to be applied at a national level.
Literature
2.
go back to reference Filippi M, Rocca MA, De Stefano N et al (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68(12):1514–1520PubMedCrossRef Filippi M, Rocca MA, De Stefano N et al (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68(12):1514–1520PubMedCrossRef
3.
go back to reference Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302PubMedCrossRef Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302PubMedCrossRef
4.
go back to reference Charil A, Yousry TA, Rovaris M et al (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol 5(10):841–852PubMedCrossRef Charil A, Yousry TA, Rovaris M et al (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol 5(10):841–852PubMedCrossRef
5.
go back to reference Miller DH, Weinshenker BG, Filippi M et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174PubMedCrossRef Miller DH, Weinshenker BG, Filippi M et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174PubMedCrossRef
6.
go back to reference (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45(7):1277–1285 (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45(7):1277–1285
7.
go back to reference Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRef Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRef
8.
go back to reference Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511PubMedCrossRef Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511PubMedCrossRef
9.
go back to reference Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8(11):987–997PubMedCrossRef Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8(11):987–997PubMedCrossRef
10.
go back to reference Filippi M, Rocca MA, Calabrese M et al (2010) Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 75(22):1988–1994PubMedCrossRef Filippi M, Rocca MA, Calabrese M et al (2010) Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 75(22):1988–1994PubMedCrossRef
11.
go back to reference Ormerod IE, Miller DH, McDonald WI et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110(Pt 6):1579–1616PubMedCrossRef Ormerod IE, Miller DH, McDonald WI et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110(Pt 6):1579–1616PubMedCrossRef
12.
go back to reference Filippi M, Gawne-Cain ML, Gasperini C et al (1998) Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 50(1):238–244PubMedCrossRef Filippi M, Gawne-Cain ML, Gasperini C et al (1998) Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 50(1):238–244PubMedCrossRef
13.
go back to reference Barkhof F, Filippi M, van Waesberghe JH et al (1997) Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 49(6):1682–1688PubMedCrossRef Barkhof F, Filippi M, van Waesberghe JH et al (1997) Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 49(6):1682–1688PubMedCrossRef
14.
go back to reference Lycklama G, Thompson A, Filippi M et al (2003) Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2(9):555–562PubMedCrossRef Lycklama G, Thompson A, Filippi M et al (2003) Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2(9):555–562PubMedCrossRef
15.
go back to reference McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef
16.
go back to reference Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846PubMedCrossRef Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846PubMedCrossRef
17.
go back to reference Swanton JK, Rovira A, Tintore M et al (2007) MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 6(8):677–686PubMedCrossRef Swanton JK, Rovira A, Tintore M et al (2007) MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 6(8):677–686PubMedCrossRef
18.
go back to reference Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 244(2):76–84PubMedCrossRef Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 244(2):76–84PubMedCrossRef
19.
go back to reference Filippi M, Horsfield MA, Ader HJ et al (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43(4):499–506PubMedCrossRef Filippi M, Horsfield MA, Ader HJ et al (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43(4):499–506PubMedCrossRef
20.
go back to reference Vrenken H, Jenkinson M, Horsfield MA, et al. (2012). Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol Vrenken H, Jenkinson M, Horsfield MA, et al. (2012). Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol
21.
go back to reference Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56(4):548–555PubMedCrossRef Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56(4):548–555PubMedCrossRef
22.
go back to reference Tomassini V, Paolillo A, Russo P et al (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253(3):287–293PubMedCrossRef Tomassini V, Paolillo A, Russo P et al (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253(3):287–293PubMedCrossRef
23.
go back to reference Rio J, Rovira A, Tintore M et al (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler 14(4):479–484PubMedCrossRef Rio J, Rovira A, Tintore M et al (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler 14(4):479–484PubMedCrossRef
24.
go back to reference Rio J, Castillo J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15(7):848–853PubMedCrossRef Rio J, Castillo J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15(7):848–853PubMedCrossRef
25.
go back to reference Sormani M, Rio J, Tintore M et al (2013) Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 19(5):605–612PubMedCrossRef Sormani M, Rio J, Tintore M et al (2013) Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 19(5):605–612PubMedCrossRef
26.
go back to reference Sormani M, Signori A, Stromillo M, De Stefano N (2013) Refining response to treatment as defined by the Modified Rio Score. Mult Scler Sormani M, Signori A, Stromillo M, De Stefano N (2013) Refining response to treatment as defined by the Modified Rio Score. Mult Scler
27.
go back to reference Freedman MS, Patry DG, Grand’Maison F, Myles ML, Paty DW, Selchen DH (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31(2):157–168PubMed Freedman MS, Patry DG, Grand’Maison F, Myles ML, Paty DW, Selchen DH (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31(2):157–168PubMed
28.
go back to reference Freedman MS, Selchen D, Arnold DL et al (2013) Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 40(3):307–323PubMed Freedman MS, Selchen D, Arnold DL et al (2013) Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 40(3):307–323PubMed
Metadata
Title
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients
Authors
Massimo Filippi
Maria A. Rocca
Stefano Bastianello
Giancarlo Comi
Paolo Gallo
Massimo Gallucci
Angelo Ghezzi
Maria Giovanna Marrosu
Giorgio Minonzio
Patrizia Pantano
Carlo Pozzilli
Gioacchino Tedeschi
Maria Trojano
Andrea Falini
Nicola De Stefano
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 12/2013
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1485-7

Other articles of this Issue 12/2013

Neurological Sciences 12/2013 Go to the issue